References

Public drug policy for children in Canada.

10.1503/cmaj.170380 · 2017 · External reference

Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers

10.1017/s0266462313000573 · 2013 · External reference

Scientific and social value judgments for orphan drugs in health technology assessment.

10.1017/s0266462316000416 · 2016 · External reference

Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.

10.1016/j.socscimed.2017.06.024 · 2017 · External reference

Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.

10.1007/s10198-017-0871-0 · 2018 · External reference

An evidence framework for off-patent pharmaceutical review for Health Technology Assessment in emerging markets.

10.1016/j.vhri.2018.01.003 · 2018 · External reference

Application of a value framework based on Multiple Criteria Decision Analysis in the context of health technology assessment: A series of case studies with decision makers across European countries.

10.1016/j.jval.2016.09.080 · 2016 · External reference

Recommendations from the European working group for value assessment and funding processes in rare diseases (ORPH-VAL).

10.1186/s13023-017-0601-9 · 2017 · External reference

What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.

10.1016/j.healthpol.2018.11.003 · 2019 · External reference

Accountable and Reasonable processes for coverage decision-making for rare disease and regenerative therapies–Which criteria should be considered and why?

10.1016/j.jval.2018.04.437 · 2018 · External reference

Ethics and economics: does programme budgeting and marginal analysis contribute to fair priority setting?

10.1258/135581906775094280 · 2006 · External reference

Prioritisation of specialist health care services; not NICE, not easy but it can be done.

10.1016/j.healthpol.2017.06.007 · 2017 · External reference

6-STEPPPs: A modular tool to facilitate clinician participation in fair decisions for funding new cancer drugs

10.1200/jop.0812001 · 2008 · External reference

“The problem is small enough, the problem is big enough”: A qualitative study of health technology assessment and public policy on drug funding decisions for children.

10.1186/s12939-020-01164-w · 2020 · External reference

PIH83 Health Technology Assessment in Child Health

10.1016/j.jval.2012.03.1115 · 2012 · External reference

Unresolved reference

External reference

Canadian trends and projections in prescription drug purchases: 2001–2023

2021 · External reference

Management of hospital formularies in Ontario: Challenges within a Local Health Integration Network

2016 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Reflecting on reflexive thematic analysis.

10.1080/2159676x.2019.1628806 · 2019 · External reference

Thematic analysis.

2019 · External reference

Unresolved reference

External reference

Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.

2020 · External reference

Variation in Health Technology Assessment and Reimbursement Processes in Europe.

10.1016/j.jval.2016.08.725 · 2017 · External reference

Addressing the affordability of cancer drugs: Using deliberative public engagement to inform health policy

10.1186/s12961-019-0411-8 · 2019 · External reference

Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).

10.1186/s13023-019-1121-6 · 2019 · External reference

Action Guide for Addressing Ethical Challenges of Resource Allocation within Community-Based Healthcare Organizations.

10.1086/jce2018292124 · 2018 · External reference

NICE and Fair? Health Technology Assessment Policy Under the UK’s National Institute for Health and Care Excellence, 1999–2018

10.1007/s10728-019-00381-x · 2020 · External reference

Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

10.2147/ceor.s134230 · 2017 · External reference

Stakeholder views on criteria and processes for priority setting in Norway: a qualitative study.

10.1016/j.healthpol.2017.04.005 · 2017 · External reference

Review: Rare diseases under different levels of economic analysis: current activities, challenges and perspectives.

10.1136/rmdopen-2018-000794 · 2018 · External reference

Community views on factors affecting medicines resource allocation: cross-sectional survey of 3080 adults in Australia.

10.1071/ah16209 · 2019 · External reference

Development of the WHO-INTEGRATE evidence-to-decision framework: An overview of systematic reviews of decision criteria for health decision-making

10.1186/s12962-020-0203-6 · 2020 · External reference

Priority setting in hospitals: fairness, inclusiveness, and the problem of institutional power differences.

10.1016/j.socscimed.2005.04.037 · 2005 · External reference

10.1093/acprof:oso/9780195149364.001.0001

10.1093/acprof:oso/9780195149364.001.0001 · 2002 · External reference

Patient empowerment and access to medicines: Insights from a scientist-patient suffering from erythropoietic protoporphyria

2019 · External reference

Governments need better guidance to maximise value for money: The case of Australia’s pharmaceutical benefits advisory committee.

10.1007/s40258-015-0220-3 · 2016 · External reference

The Health Equity Impact Assessment: A case study in COVID-19 visitor policy.

2021 · External reference

Generating Health Technology Assessment evidence for rare diseases.

10.1017/s0266462314000464 · 2014 · External reference

Ethical and Social Values for Paediatric Health Technology Assessment and Drug Policy.

2022 · External reference